Articles

P3.14 Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models

BJH - volume 6, issue Abstract Book BHS, january 2015

M. Binsfeld , M. Hannon , S. Humblet-Baron , Y. Beguin MD, PhD, F. Baron MD, PhD, J. Caers MD, PhD

Read more

Update on the initial therapy of multiple myeloma

BJH - volume 5, issue 4, december 2014

M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, KL. Wu MD, PhD, C. Doyen MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD

Summary

With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).

(BELG J HEMATOL 2014;5(4):125–36)

Read more

O.2 Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

M. Binsfeld , Y. Beguin MD, PhD, L. Belle , E. Otjacques , M. Hannon , A. Briquet PhD, P. Drion , B. Bogen , F. Baron MD, PhD, J. Caers MD, PhD

Read more

P1.04 Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines

BJH - volume 5, issue Abstract Book BHS, january 2014

M. Binsfeld , R. Heusschen PhD, V. Lamour , E. Van Valckenborgh PhD, A. Bellahcène , F. Baron MD, PhD, Y. Beguin MD, PhD, J. Caers MD, PhD

Read more

P2.18 Responding patients show durable responses to bendamustine in double refractory multiple myeloma patients

BJH - volume 5, issue Abstract Book BHS, january 2014

J. Caers MD, PhD, M-C. Vekemans MD, I. Vande Broek MD, PhD, V. Maertens MD, P.H. Mineur , G. Bries MD, PhD, E. Vandeneste , G. Vanstraelen , K. Beel MD, PhD, F. Leleu , H. Demuynck MD, C. Scheurmans , A. Van de Velde MD, W. Schroyens MD, PhD, K.L. Wu MD, PhD, N. Meuleman MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD

Read more

P2.20 Galectin expression in the multiple myeloma microenvironment

BJH - volume 5, issue Abstract Book BHS, january 2014

J. Muller MSc, J. Caers MD, PhD, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD

Read more

O.4 Combination of regulatory T cells injection with rapamycin for treatment of chronic Graft-versus-Host disease

BJH - 2013, issue BHS Abstractbook, january 2013

L. Belle , M. Binsfeld , M. Hannon , J. Caers MD, PhD, A. Briquet PhD, M. Menten , Y. Beguin MD, PhD, S. Humblet , F. Baron MD, PhD

Read more